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coronary artery disease (CAD) undergoing percutaneous coro-
nary intervention (PCI) were electively treated with SES or BMS
(sequential control design). Baseline socio-demographic and
coronary risk factors, major adverse coronary events (MACE),
including death, myocardial infarction, coronary artery bypass
surgery and re-PCI in target vessel, as well as disease-related
direct and indirect costs were documented by standardised ques-
tionnaires completed by patients and physicians through 18
months following PCI. All results are adjusted for age, gender,
household status, 3-vessel heart disease and number of stents.
P-values are from tests of interaction. RESULTS: From April
2003 to June 2005, 658 patients were treated with SES (87%
male, mean age 63  9, 24% diabetic) and 294 patients with
BMS (79% male, mean age 64  10, 20% diabetic). After 18
months, 23% of SES and 27% of BMS patients with diabetes had
suffered MACE in comparison to 9% of SES and 18% of BMS
patients without diabetes (no signiﬁcant difference in the effect of
SES in the presence of diabetes, adjusted = 0.354). In diabetic
patients, SES and BMS incurred total costs of EUR 14,357
and 10,909, respectively. In non-diabetic patients, SES and
BMS costs totalled EUR 13,241 and 11,215, respectively (p
adjusted = 0.164). In diabetic patients, the cost-effectiveness of
SES vs. BMS was EUR 92,400 per patient free from MACE and
in non-diabetic patients, EUR 16,163. CONCLUSIONS: In this
subgroup analysis, MACE in patients with diabetes did not
appear to be inﬂuenced by stent type, whereas in non-diabetic
patients SES use resulted in lower MACE. SES implantation was
less cost-effective in patients with diabetes than in non-diabetic
patients.
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OBJECTIVES: Use of niacin extended-release with statin mono-
therapy (SM) for combined lipid target attainment (CLTA) of
LDL-C, HDL-C, and triglycerides (TG) has been limited. The
objective was to compare real-world CLTA among patients
receiving niacin extended-release+any statin (NER+S) versus
ﬁxed-dose simvastatin+ezetimibe (S+E) combination therapy.
METHODS: A retrospective analysis was conducted on patients
aged 18 years, newly initiating NER+S or S+E therapy between
July 1, 2000–June 30, 2006 (index date), with health plan eligi-
bility of at least 12 months pre- and post-index date, and at
non-target HDL-C (<40 mg/dL) and TG levels (>150 mg/dL) at
index date using a large integrated research claims database.
CLTA, assessed at the last laboratory visit within 12 months of
index date, was deﬁned according to NCEP ATP III, ADA, and
AHA Women’s guidelines where appropriate. A propensity score,
controlling for differences in index date age, gender, LDL-C,
HDL-C, and TG levels, was included as a covariate in a multi-
variate logistic regression model comparing odds of achieving
CLTA between treatment groups. RESULTS: A total of 883
patients were analyzed, 445 initiating NER+S and 438 initiating
S+E. NER+S patients were signiﬁcantly older (54  9 years
vs. 51  8 years; p < 0.0001), more male (81% vs. 55%;
p < 0.0001), hypertensive (80% vs. 67%; p < 0.0001), and with
prior cardiovascular disease (CVD) (46% vs. 17%; p < 0.0001)
than S+E patients. All NER+S patients and some S+E patients
(48%) were prescribed SM prior to index date. Mean baseline
values for LDL-C (98  36 vs. 136  43 mg/dL; p < 0.0001)
and HDL-C (37  9 vs.44  11 mg/dL; p < 0.0001) were signiﬁ-
cantly lower among NER+S patients. Logistic regression analysis
indicated 64% (OR: 1.64; 95% C.I.: 1.02–2.61) increased like-
lihood of CLTA among NER+S patients versus S+E patients.
CONCLUSIONS: Dyslipidemia patients initiating NER+S
therapy were more likely to achieve CLTA than patients initiating
S+E therapy in a real-world setting, thus implying a greater
potential reduction in cardiovascular risk.
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OBJECTIVES: To assess the effectiveness of clopidogrel in addi-
tion to aspirin versus aspirin alone after acute coronary syn-
drome (ACS) in an Australian context. METHODS: A Markov
model was constructed to simulate the onset of major cardiovas-
cular events (composite of myocardial infarction, ischemic stroke
and cardiovascular death), major bleeding events and non-
cardiovascular death in a representative cohort of 1000 subjects
experiencing ACS. In the ﬁrst year post ACS, underlying risks
of events were drawn from the nationwide Australian Acute
Coronary Syndromes Prospective Audit (ACACIA) registry
(n = 2553). In subsequent years, risks from Australian partici-
pants of the Reduction in Atherothrombosis for Continued
Health (REACH) registry (n = 2567) were used. Decision analy-
sis compared the two interventions and follow-up was simulated
for ten years. Relative risks of cardiovascular and bleeding events
associated with clopidogrel were drawn from the Clopidogrel in
Unstable Angina to Prevent Recurrent Events (CURE) trial, and
assumed to be sustained as long as subjects remained on treat-
ment. Uncertainty analyses were undertaken via Monte Carlo
simulation. RESULTS: The modeled outcomes from the simu-
lated follow-up of 1000 subjects in the ten year model were
major CV events, major bleeding events and deaths. There were
fewer CV events and deaths in the clopidogrel arm but more
bleeding events than aspirin. The number needed to treat (NNT)
to avoid a major CV event was 14 (9–29); to avoid a death was
33 (14–207). Overall, there were 8413 life years gained in clo-
pidogrel compared with 8191 in aspirin alone. CONCLUSIONS:
In the simulated cohort, the addition of clopidogrel to aspirin
represents a highly effective strategy for the secondary prevention
of death and cardiovascular events following ACS. Although
there is a small increase in bleeding in the simulated cohort, the
net effect remains a signiﬁcant prevention of cardiovascular
events, saving of lives and years of life gained.
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OBJECTIVES: The aim of this systematic review (SR) is to
compare efﬁcacy and safety of bosentan, epoprostenol, iloprost,
sildenaﬁl and treprostinil with conventional treatment (CT)
in patients with pulmonary arterial hypertension (PAH).
METHODS: Analysis was performed according to “Polish
A382 Abstracts
Guidelines on Health Technology Assessment”, 2007 and
“Cochrane Handbook for Systematic Reviews of Interventions”.
In order to identify RCTs medical databases were searched:
e.g. Medline, EmBase and Cochrane Library. Calculations and
metaanalyses were performed using StatsDirect statistical soft-
ware. RESULTS: Nineteen RCTs (treatment period 2–16 weeks),
in which a total number of 1795 patients with PAH participated,
were included in the SR. All patients continued CT with antico-
agulants, vasodilators, diuretics and/or digitalis glycosides
Bosentan, epoprostenol, iloprost and sildenaﬁl signiﬁcantly
increase exercise capacity (according to the NYHA classiﬁca-
tion) comparing to placebo in the PAH population: bosentan
vs. placebo: OR = 2.25 (95%CI: 1.21; 4.18); epoprostenol vs.
placebo: OR = 37.99 (95%CI: 8.43; 171.22); iloprost vs.
placebo: OR = 2.25 (95%CI: 1.02; 5.13), sildenaﬁl vs. placebo:
OR = 6.94 (95%CI: 2.78; 17.31). In bosentan, iloprost, sildenaﬁl
and treprostinil groups signiﬁcantly higher improvement in exer-
cise capacity, measured using the 6-minute walk test, was found
comparing to placebo: WMD = 43.33 m (95%CI: 27.55; 59.12)
for bosentan vs. placebo; 36.4 m (p = 0.004)—iloprost vs.
placebo; 55.82 m (95%CI: 38.03; 73.61)—sildenaﬁl vs. placebo
and 16.00 m (95%CI: 4.40; 27.60)—treprostinil vs. placebo. In
safety analysis no statistically signiﬁcant differences were
observed between bosentan and placebo as well as sildenaﬁl and
placebo groups. Comparing to placebo, in epoprostenol group
signiﬁcantly more often jaw pain, nausea and diarrhea occurred,
in iloprost group there was higher incidence of serious syncope or
ﬂushing and jaw pain and in the treprostinil group—sudden
vasodilation, edema, jaw pain and reaction, pain, hematoma or
induration at the injection site. CONCLUSIONS: The use of
these ﬁve drugs in addition to CT is more effective than CT alone.
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OBJECTIVES: The effectiveness of drug-eluting stents (DES) and
bare-metal stents (BMS) in reducing restenosis and rate of major
adverse cardiac events (MACE) in selected patients has been
demonstrated by the randomized controlled trials. Despite the
better efﬁcacy of DES over BMS in reducing revascularization,
the initial cost of DES is much higher than BMS, which limits its
use in clinical practice. We aimed to evaluate the clinical outcome
of BMS and DES placement in coronary artery disease patients
and estimate the cost of BMS and DES placement in a Chinese
population. METHODS: It was a retrospective cross-sectional
study. We included all patients who underwent PCI with stent
placement of either DES or BMS in a tertiary public hospital in
Hong Kong during January to December 2005. Patients were
followed up for the occurrence of MACE within 12 months of
the index stent placement. MACE was deﬁned as cardiac death,
non-fatal myocardial infarction and target lesion revasculariza-
tion. Direct medical costs were estimated based on the proce-
dural cost, hospitalization, medications, cardiac follow-up and
repeated interventions taken. RESULTS: This analysis included
447 patients. Twelve-month MACE rate was 10.6% in BMS
versus 3.0% in DES (p = 0.001). Rate of cardiac death was
2.9% in BMS versus 0.0% in DES group (p = 0.109). The
mean 12-month cost per patient after index PCI was
USD 9802.9  8503.8 (median = 8721.8) in BMS and USD
10052.1  5624.9 (median = 8786.7) in DES. On average, DES
costs USD 1605.1 more than BMS per patient. CONCLUSIONS:
DES demonstrated a signiﬁcant reduction in 12-month MACE
compared with BMS. Although DES carried a higher procedural
cost, it had similar 12-month costs with BMS due to less post-
PTCA intervention. DES was proved to be cost-effective to be
used in Hong Kong public hospitals.
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OBJECTIVES: To explore the efﬁcacy of irbesartan in reducing
blood pressure (BP) compared to candesartan, in a real-world
setting. METHODS: We analysed the records of 10,338 (5,425
candesartan; 4,913 irbesartan) adult patients with hypertension
who were initiated on the two agents between 1998 and 2006
using the UK THIN GP database. The analyses presented report
the comparisons for General hypertensive patients (systolic BP
(SBP) 140 mmHg, diastolic BP (DBP) 90 mmHg) and Severe
hypertensive patients (SBP  180 mmHg, DBP  110 mmHg)
on either ARB over the ﬁrst 2 years of treatment. RESULTS: In
the General hypertensive group mean SBP reductions at 1 year
reached 14.7 mmHg for irbesartan vs. 13.6 mmHg for cande-
sartan. Mean DBP reductions reached 8.5 mmHg for irbesartan
and 7.1 mmHg for candesartan. In the Severe group, mean SBP
reductions reached 31.6 mmHg for irbesartan vs. 31.2 mmHg
for candesartan. Mean DBP reductions reached 15.8 mmHg for
irbesartan vs. 13.4 mmHg for candesartan. Similar comparisons
were observed in the second year analysis. All but one of the
comparisons were statistically signiﬁcant in a multivariate analy-
sis after adjusting for baseline BP, age, sex, weight, diabetes
status, practice effect, socioeconomic status, 1st line vs. subse-
quent line usage, number of prior comorbidities, hypertensive
diagnosis status and type of and number of co-therapies pre-
scribed. In the General hypertensive population, patients receiv-
ing irbesartan showed a greater mean reduction in SBP of
1.18 mmHg (p < 0.001) and of 0.55 mmHg (p < 0.001) in DBP
over 2 years compared to those receiving candesartan. Similar
differences among therapies were observed in Severe patients,
1.79 mmHg in SBP (p = 0.02), -0.10 mmHg in DBP (p = 0.747).
Signiﬁcance may have been affected by the small number of
patients in the Severe group. CONCLUSIONS: In a real-world
setting, patients receiving irbesartan are observed to achieve
greater BP reductions compared to those receiving candesartan.
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OBJECTIVES: Missing a single dose is the most common error in
patients on once-daily antihypertensives. In this study we
explored whether a drug which maintains its efﬁcacy for >48 hrs
offers adequate blood pressure (BP) reduction in the face of
typical dosing errors. METHODS: Mean BP reduction and rate
of loss of efﬁcacy after stopping the drug were derived from a
randomized study comparing aliskiren, ramipril, and irbesartan
in 654 hypertensives. An independent database of dosing histo-
ries, compiled in patients on once-daily antihypertensives and
recording electronically whether and when doses were taken, was
used to describe the distribution of dosing errors. From this, each
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